Yescartar (B-cell lymphoma) and Kymriahr (pediatric B-ALL) both are based on CAR T-cells that recognize CD19 on the surface of malignant B-cells [7,9]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.